DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/f4grlw/lymphoma_drug) has announced the addition of the "Lymphoma Drug Pathway Analyzer 2013" report to their offering.

There are today at least 317 targeted molecular therapies known to affect more than 228 specific intracellular signaling pathways for the treatment of lymphoma. The rational for this plethora of treatment strategies is based on our increasing understanding of the 201 drug targets that are included in this drug-pathway analyzing tool. No less than 195 of these have been recorded with mutations and 44 drug targets have mutations which have been causally implicated in cancer.

Pathway Coverage

• BioCarta# 227 Pathways
• KEGG# 165 Pathways
• NCI-Nature# 228 Pathways
• NetPath# 32 Pathways

Pipeline Coverage

• Marketed# 38
• Registered# 1
• Pre-registration# 4
• Phase III# 22
• Phase II# 118
• Phase I# 147
• Preclinical# 69
• No Data# 6
• Suspended# 1
• Ceased# 93

The continuous identification of drug targets and pathways that are altered in cancer is not only crucial for our understanding of cancer biology, but also to search for new targets for early diagnosis and improved treatment designs. Consequently, it has never before been as important to rapidly translate systems biology of disease and therapeutics to actionable pipeline decisions to ensure that the optimal market conditions exist by the time a candidate drug is commercialized.

This high-level drug-pathway analyzer lets you interact with the lymphoma pipeline in a whole different than way than you ever done before. Its capabilities moves you beyond powerful competitive intelligence to an opportunity seeking tool which lets you, by means of both present and emerging scientific knowledge, analyze the lymphoma pipeline for interesting compounds which affect and/or fit your purposes, may it be benchmarking, in/out-licensing, combination therapy options, drug repositioning, indication expansion etc.

Reasons To Buy

- Map the competition and find suitable benchmarking/licensing drugs based on specific pathways and drug properties

- Uncover potential indication expansion areas for your drug portfolio

- Reveal repositioning opportunities for your older, shelved drugs

- Evaluate the progression and success of targeting certain pathways by different tumor types

- Investigate drugs which affect crosstalk between key pathways

- Investigate different combination therapy options available to you in various cancer types. Use this tool to look for the most-efficient ways to combine your drug with other targeted agents.

- Find possible adjuvant therapy settings with other drugs.

For more information visit http://www.researchandmarkets.com/research/f4grlw/lymphoma_drug